Literature DB >> 29685907

Warning of an increased risk of vertebral fracture after stopping denosumab.

Christopher Symonds1, Gregory Kline2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29685907      PMCID： PMC5915244          DOI： 10.1503/cmaj.180115

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  12 in total

1.  Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

Authors:  Henry G Bone; Michael A Bolognese; Chui Kin Yuen; David L Kendler; Paul D Miller; Yu-Ching Yang; Luanda Grazette; Javier San Martin; J Christopher Gallagher
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

2.  Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate.

Authors:  Brett A Lenart; Dean G Lorich; Joseph M Lane
Journal:  N Engl J Med       Date:  2008-03-20       Impact factor: 91.245

3.  Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.

Authors:  A Modi; S Sajjan; R Insinga; J Weaver; E M Lewiecki; S T Harris
Journal:  Osteoporos Int       Date:  2017-01-05       Impact factor: 4.507

4.  An Essential Warning.

Authors:  Benjamin Z Leder
Journal:  J Bone Miner Res       Date:  2018-01-04       Impact factor: 6.741

Review 5.  Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.

Authors:  Elena Tsourdi; Bente Langdahl; Martine Cohen-Solal; Bérengere Aubry-Rozier; Erik Fink Eriksen; Nuria Guañabens; Barbara Obermayer-Pietsch; Stuart H Ralston; Richard Eastell; M Carola Zillikens
Journal:  Bone       Date:  2017-08-05       Impact factor: 4.398

Review 6.  Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases.

Authors:  Athanasios D Anastasilakis; Stergios A Polyzos; Polyzois Makras; Berengere Aubry-Rozier; Stella Kaouri; Olivier Lamy
Journal:  J Bone Miner Res       Date:  2017-03-13       Impact factor: 6.741

7.  10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.

Authors:  Henry G Bone; Rachel B Wagman; Maria L Brandi; Jacques P Brown; Roland Chapurlat; Steven R Cummings; Edward Czerwiński; Astrid Fahrleitner-Pammer; David L Kendler; Kurt Lippuner; Jean-Yves Reginster; Christian Roux; Jorge Malouf; Michelle N Bradley; Nadia S Daizadeh; Andrea Wang; Paula Dakin; Nicola Pannacciulli; David W Dempster; Socrates Papapoulos
Journal:  Lancet Diabetes Endocrinol       Date:  2017-05-22       Impact factor: 32.069

8.  Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access.

Authors:  A M Burden; M Tadrous; A Calzavara; S M Cadarette
Journal:  Osteoporos Int       Date:  2015-01-21       Impact factor: 4.507

Review 9.  Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review.

Authors:  Carolyn J Crandall; Sydne J Newberry; Allison Diamant; Yee-Wei Lim; Walid F Gellad; Marika J Booth; Aneesa Motala; Paul G Shekelle
Journal:  Ann Intern Med       Date:  2014-11-18       Impact factor: 25.391

10.  Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada.

Authors:  A M Burden; J M Paterson; D H Solomon; M Mamdani; D N Juurlink; S M Cadarette
Journal:  Osteoporos Int       Date:  2011-05-21       Impact factor: 4.507
View more
  4 in total

Review 1.  Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction.

Authors:  Muhammad Asad Fraz; Faiza Hassan Warraich; Sami Ullah Warraich; Muhammad Junaid Tariq; Zabih Warraich; Ali Younas Khan; Muhammad Usman; Awais Ijaz; Pavan Tenneti; Adeela Mushtaq; Faisal Akbar; Zaina Shahid; Zeeshan Ali; Hafiz Muhammad Fazeel; Cesar Rodriguez; Aboo Nasar; Ali McBride; Faiz Anwer
Journal:  Crit Rev Oncol Hematol       Date:  2019-02-27       Impact factor: 6.312

Review 2.  The current situation in the approach to osteoporosis in older adults in Turkey: areas in need of improvement with a model for other populations.

Authors:  Gulistan Bahat; Nezahat Muge Catikkas; Dilek Gogas Yavuz; Pinar Borman; Rengin Guzel; Jean Yves Reginster
Journal:  Arch Osteoporos       Date:  2021-11-30       Impact factor: 2.617

3.  Real-World Safety and Effectiveness of Denosumab in Patients with Osteoporosis: A Prospective, Observational Study in South Korea.

Authors:  Yumie Rhee; Dong-Gune Chang; Jeonghoon Ha; Sooa Kim; Yusun Lee; Euna Jo; Jung-Min Koh
Journal:  Endocrinol Metab (Seoul)       Date:  2022-06-03

4.  Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020.

Authors:  Sara Jane Cromer; Kristin M D'Silva; Elaine W Yu; Joan Landon; Rishi J Desai; Seoyoung C Kim
Journal:  J Gen Intern Med       Date:  2021-06-07       Impact factor: 6.473
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.